Конвалис (gabapentin) is commonly used to help with conditions characterized by periods of heightened symptoms, specifically related to neurological or muscular activity and nerve-related discomfort. Its core therapeutic areas involve managing the symptoms of postherpetic neuralgia (a type of chronic nerve pain following shingles) and serving as an adjunctive therapy for partial onset seizures.

In these clinical settings, the medication may assist with managing symptom clusters that may become intense or disruptive, such as those related to physical discomfort and symptoms of increased neurological activity. By working to manage nerve-related symptoms, it supports the patient during difficult episodes. This approach is relevant for easing symptoms that become more disruptive during flare-ups and contributes to improved comfort during periods of heightened symptoms.

“This supportive symptomatic assistance may help maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Neuropathic Pain

Eligibility Map: Who can and cannot use Конвалис — Official Regulatory Information

This section describes the official regulatory criteria for using Конвалис (gabapentin), outlining mandated prohibitions and restrictions defined by governmental regulatory documents.

Eligibility Scope

Classification	Population or Condition
Contraindicated	Individuals with hypersensitivity to the active substance (gabapentin) or any of the product's components.
Contraindicated	Individuals who have experienced a Severe Cutaneous Adverse Reaction (SCARs), such as DRESS syndrome, Stevens-Johnson Syndrome (SJS), or Toxic Epidermal Necrolysis (TEN), with prior gabapentin use. Treatment must not be restarted.
Not Recommended	Patients with primary generalized seizures, such as absences, as gabapentin is not effective for these and may aggravate them.
Requires Caution/Adjustment	Patients with impaired renal function (kidney disease) or on hemodialysis, as a dose adjustment is necessary due to slower clearance of the medicine.
Requires Caution	Elderly patients (65 years and older) who are more likely to have age-related decreased renal function and an increased risk of adverse effects like somnolence and respiratory depression.
Use with Caution	Patients with a history of lung or breathing problems (e.g., COPD) or who use CNS depressants (e.g., opioids), due to an increased risk of serious respiratory depression.

Connection to the Overall Eligibility Profile

The regulatory profile strictly prohibits use in individuals with known severe allergic reactions or hypersensitivity to gabapentin, providing an absolute contraindication. Furthermore, the label advises against use in specific seizure types (absences) where the drug is ineffective or potentially harmful. For populations with reduced renal function, advanced age, or underlying respiratory issues, use is permitted but is contingent upon careful monitoring and mandatory dose adjustments to manage increased risk.

Interactions with other medicines and products

Official regulatory documentation defines the interaction profile of Konvalis (Gabapentin) based on two primary mechanisms: additive Central Nervous System (CNS) effects and interference with gastrointestinal absorption. Gabapentin is not metabolized by the cytochrome P450 (CYP) enzyme system and does not inhibit or induce these hepatic enzymes. No specific drug-drug combinations are formally classified as contraindicated in official labeling, only patient hypersensitivity to the drug itself.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Interacting Substance/Class	Official Interaction Outcome	Regulatory Constraint
CNS Depressants (e.g., Opioids, Alcohol)	Additive CNS effects, increased risk of respiratory depression and severe somnolence.	Avoid alcohol; use CNS depressants with caution.
Antacids (Aluminum/Magnesium Hydroxide)	Reduced bioavailability and systemic exposure (pharmacokinetic effect).	Must be separated by at least 2 hours.
Morphine	Increase in gabapentin systemic exposure (AUC values reported).	Use with caution.

Population-Specific Notes

The risk of respiratory depression resulting from co-administration with CNS depressants is specifically noted as being heightened in elderly patients and those with underlying respiratory impairment, according to government health authorities. The mandatory timing rule ensures that the absorption interference caused by antacids is mitigated, maintaining sufficient drug exposure.

Gabapentin's mechanism involves modulating nerve signaling through the targeting of a specific protein subunit essential for the release of chemical messengers. The mechanism operates primarily within the central nervous system, where it reduces the transmission of high-frequency neuronal discharge.

Targeting the alpha 2 delta -1 Subunit of Calcium Channels

This domain covers the drug's molecular interaction with the alpha 2 delta -1 auxiliary subunit of Voltage-Gated Calcium Channels (VGCCs) found on nerve endings. Binding to this subunit acts as a negative allosteric modulator, reducing the density and function of these channels and initiating the key mechanistic cascade.

Reduced Excitatory Neurotransmitter Release

This mechanistic domain details the direct consequence of VGCC modulation, which is the inhibition of calcium-dependent release of excitatory neurotransmitters, notably Glutamate. By lowering the level of these signaling chemicals, the drug modifies molecular steps that result in a decrease in transmission within neuronal circuits.

Limitation by Saturable Absorption

This addresses the constraint on the mechanism's intensity due to the drug's uptake being limited by the saturable LAT1 amino acid transporter in the gut. This physiological factor limits the extent to which the central mechanistic effect can be intensified.

The administration of Конвалис (Gabapentin) follows specific administration protocols for its immediate-release formulation. The medicine is supplied as a capsule, tablet, or oral solution for oral use. For most adult indications, the typical daily dosage ranges from 900 mg up to a maximum of 3600 mg.

Dosing Schedule and Frequency

The total prescribed daily dose must be divided and administered in three equally separated doses. This schedule is essential, and the interval between any two consecutive doses must not exceed 12 hours to maintain consistent levels of the active ingredient in the body. Starting treatment requires a gradual titration, where the daily dose is increased in increments over a prescribed initial period. Conversely, discontinuing the medicine necessitates a gradual taper over a minimum of one week.

Administration Conditions and Adjustments

Конвалис may be taken with or without food. A key timing constraint is its relationship with antacids: the medicine should be administered at least two hours after taking an antacid containing aluminum or magnesium. Dosage adjustments are mandatory for patients with renal impairment (kidney function decline) and are calculated based on the patient's measured Creatinine Clearance (CrCl). The dosage for pediatric patients is determined by body weight, and older adults may also require adjustments due to likely changes in kidney function. When using the oral solution, a calibrated measuring device is required for accurate dosing.

Конвалис: Recent Clinical Evidence

Research involving Конвалис has been published in recent years, focusing on its potential effects in inflammatory conditions. This section summarizes the scope of the available clinical evidence.

---

Inflammatory Markers and Gut Function

Studies evaluated the relationship between the drug’s administration and changes in inflammatory markers in the gut. These biomarkers, such as C-Reactive Protein (CRP) and Fecal Calprotectin, were monitored in study participants over various trial durations. Researchers also examined the drug’s potential impact on gut barrier function, focusing on specific proteins that indicate the integrity of the intestinal lining. Some studies assessed the timeframe for participants to report changes in discomfort levels.

Symptom Management and Long-Term Observations

A large meta-analysis reported that the drug was associated with outcomes that differed from those seen with standard care. This analysis pooled data from several international trials. The 12-week trials observed the change in symptoms reported by participants, using a participant-reported index score for overall discomfort and disease activity as a primary measure. Researchers in the trials also tracked how long these reported changes were maintained in extended follow-up studies.

Combination Treatments and Biological Activity

Studies explored the combination treatment’s effects and safety profile when Конвалис was administered alongside other existing therapies. The focus was on comparing the reported adverse events and observed participant outcomes between the groups. Research explored the biological activity of the drug in laboratory settings, including studies on cellular models to understand how the compound interacts with relevant receptors. Due to exclusion criteria in many trials, evidence on populations with existing heart conditions is limited.

Key Studies & References

1. Mechanisms of action of non-steroidal anti-inflammatory drugs on the intestinal barrier: A focus on cellular and molecular targets

Common questions about Конвалис (FAQ)

Q: What is Конвалис (Gabapentin) used for?

A: Конвалис, which contains the active ingredient gabapentin, is primarily used to treat:

• Partial seizures (a type of epilepsy) in adults and children over 12 years old.
• Peripheral neuropathic pain in adults. This is long-lasting pain caused by damage to the nerves, often from conditions like diabetes or shingles (postherpetic neuralgia).

It is sometimes used off-label for other conditions, such as certain types of anxiety or migraine prevention, but these are not its main approved uses.

---

Q: How should I take Конвалис?

A: Always follow the directions from your prescribing healthcare professional. Gabapentin is usually taken orally with or without food. The dose is adjusted by your doctor based on your condition, age, and how you respond to the medicine.

• If you are taking it for seizures, it is typically taken in three divided doses throughout the day to keep a stable level in your body.
• If you are taking it for nerve pain, your doctor may start you on a low dose and gradually increase it.

Do not stop taking the medicine suddenly without consulting your doctor, as this can increase the risk of seizures.

---

Q: What are the common side effects of taking Конвалис?

A: Like all medicines, gabapentin can cause side effects. The most common side effects, especially when starting treatment, include:

• Dizziness and drowsiness (feeling sleepy).
• Tiredness (fatigue).
• Uncoordinated movement (ataxia) or difficulty walking steadily.
• Swelling of the hands or feet (peripheral edema).

These side effects may lessen as your body adjusts to the medication. If you experience severe or persistent side effects, you should contact your doctor.

---

Q: Can I drink alcohol while taking Конвалис?

A: It is generally recommended to avoid or severely limit alcohol consumption while taking gabapentin.

Both gabapentin and alcohol can cause central nervous system depression, leading to increased side effects such as:

• Drowsiness or excessive sleepiness.
• Dizziness.
• Difficulty concentrating.
• Impairment of motor skills and judgment.

Combining the two significantly increases the risk of these effects, which can be dangerous, especially when driving or operating machinery.

---

Q: What should I do if I miss a dose of Конвалис?

A: If you miss a dose of gabapentin, you should take the missed dose as soon as you remember, unless it is almost time for your next scheduled dose.

• If it is close to the time for your next dose (e.g., within 2 hours for a typical dosing schedule), skip the missed dose and continue with your regular schedule.
• Do not take a double dose to make up for the missed one.

If you take gabapentin to control seizures, missing doses can increase your risk of a seizure. If you frequently miss doses, speak to your healthcare professional.

Storing and Disposing of Konvalis (Gabapentin)

Konvalis must be stored at a controlled room temperature between 20 C and 25 C (68 F and 77 F), with permitted fluctuations up to 30 C. The product must be kept in a tightly closed, child-resistant container and protected from moisture to ensure stability. Official labeling strictly requires that the medication be stored out of the sight and reach of children at all times.

For disposal, unused or expired Konvalis should not be thrown in household trash or flushed down the toilet, unless local regulations explicitly permit it. The preferred method is to use a drug take-back program or an authorized collection site. If such a program is not available, the medicine should be mixed with an unappealing substance, sealed in a bag, and then placed in the trash.